Pablo Berlanga
A5030894218- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Childhood Cancer Survivors' Quality of Life
- Cancer, Hypoxia, and Metabolism
- Neurofibromatosis and Schwannoma Cases
- Pancreatic and Hepatic Oncology Research
- Cardiac tumors and thrombi
- CAR-T cell therapy research
- Bone Tumor Diagnosis and Treatments
- Renal and related cancers
- Vascular Tumors and Angiosarcomas
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- Cardiac electrophysiology and arrhythmias
- Tumors and Oncological Cases
- Child and Adolescent Health
- Cancer Treatment and Pharmacology
- Pharmaceutical studies and practices
- Palliative Care and End-of-Life Issues
- Genetic factors in colorectal cancer
- Adrenal and Paraganglionic Tumors
Institut Gustave Roussy
2019-2025
Université Paris-Saclay
2020-2024
Inserm
2024
Assistance Publique – Hôpitaux de Paris
2021
Hôpital Cochin
2021
Hospital Universitari i Politècnic La Fe
2013-2018
Instituto de Investigación Sanitaria La Fe
2013-2017
Leitat Technological Center
2014-2017
Pediatric Oncology Group
2014
Weatherford College
2013
Abstract MAPPYACTS (NCT02613962) is an international prospective precision medicine trial aiming to define tumor molecular profiles in pediatric patients with recurrent/refractory malignancies order suggest the most adapted salvage treatment. From February 2016 July 2020, 787 were included France, Italy, Ireland, and Spain. At least one genetic alteration leading a targeted treatment suggestion was identified 436 (69%) successful sequencing; 10% of these alterations considered “ready for...
BackgroundAddition of anti-GD2 antibodies to temozolomide-based chemotherapy has demonstrated increased antitumor activity and progression-free survival in patients with relapsed/progressive high-risk neuroblastoma. However, chemo-immunotherapy is not yet uniformly approved for this indication. This study presents the experience neuroblastoma treated within off-label use program Neuroblastoma Committee French Society Pediatric Oncology (SFCE).MethodsDinutuximab beta (dB) was administered...
Purpose of review There is an unmet need to improve outcomes for patients Ewing sarcoma, a rare, aggressive sarcoma with peak incidence in adolescents and young adults (AYA). Current therapy at diagnosis involves multiagent chemotherapy local therapy, but despite intensification treatment, those metastases recurrent disease have poor outcomes. Recent findings Improved understanding biology has identified novel targets promising activity patients, including tyrosine kinase inhibitors that are...
<div>AbstractPurpose:<p>Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There limited data on the clinical course affected patients.</p>Experimental Design:<p>We conducted an international retrospective cohort study patients with TRK fusion–driven tumors.</p>Results:<p>A total 119 were identified. The median age at time diagnosis was 4.5 years. majority reported to have a histology consistent...
<p>Supplementary Figure S1. Diagram of population patients.</p>
<p>Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) LGG: Low-grade glioma, HGG: High-grade glioma</p>
<p>Supplementary Data S1. Definition of response, Description response criteria used by sites to evaluate tumor extend resection, resection sites.</p>
Lung metastasis is the major cause of death in osteosarcoma patients. However, molecular mechanisms underlying this remain poorly understood. To identify key molecules related with pulmonary pediatric osteosarcomas, we analyzed high‐throughput miRNA expression a cohort 11 primary tumors and 15 lung metastases. Results were further validated an independent 10 6 In parallel, performed immunohistochemical analysis activated signaling pathways 36 osteosarcomas. Only phospho‐AKT associated lower...
Purpose: Despite advances in multimodal therapy, neuroblastomas with hemizygous deletion chromosome 11q (20%-30%) undergo consecutive recurrences poor outcome. We hypothesized that patients 11q-loss may share a druggable molecular target(s) can be exploited for precision medicine strategy to improve treatment outcome.Experimental Design: SNP arrays were combined next-generation sequencing (NGS) precisely define the deleted region 17 primary and identify allelic variants genes relevant...
Innovative anticancer therapies for children, adolescents, and young adults are regularly prescribed outside their marketing authorization or through compassionate use programs. However, no clinical data of these prescriptions is systematically collected.To measure the feasibility collection safety efficacy off-label innovative therapies, with adequate pharmacovigilance declaration to inform further development medicines.This cohort study included patients treated at French pediatric...
Abstract Pediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial (NCT02613962). To date, 131 PDX were established following heterotopical and/or orthotopical implantation immunocompromised mice: 76 sarcomas, 25 other solid tumors, 12 central nervous system 15 acute leukemias, 3 lymphomas. establishment rate was 43%. Histology, whole...